Trimetazidine (TMZ), also indicated for angina, targets 3-Keto Acyl Thiolase (Acaa), a key enzyme in fatty acid β-oxidation, facilitating a metabolic shift towards glycolysis over FAO for energy needs (Fig 3A). This evidence concerns the gene ACAA1 and angina pectoris.